- Home
- YOSH vs GRI Comparison
YOSH vs GRI Comparison
Compare YOSH & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- GRI
- Stock Information
- Founded
- YOSH 2016
- GRI 2018
- Country
- YOSH United States
- GRI United States
- Employees
- YOSH N/A
- GRI N/A
- Industry
- YOSH Restaurants
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- GRI Health Care
- Exchange
- YOSH Nasdaq
- GRI Nasdaq
- Market Cap
- YOSH 5.0M
- GRI 5.6M
- IPO Year
- YOSH 2022
- GRI N/A
- Fundamental
- Price
- YOSH $8.76
- GRI $0.42
- Analyst Decision
- YOSH
- GRI Strong Buy
- Analyst Count
- YOSH 0
- GRI 2
- Target Price
- YOSH N/A
- GRI $11.50
- AVG Volume (30 Days)
- YOSH 187.8K
- GRI 181.8K
- Earning Date
- YOSH 03-31-2025
- GRI 03-27-2025
- Dividend Yield
- YOSH N/A
- GRI N/A
- EPS Growth
- YOSH N/A
- GRI N/A
- EPS
- YOSH N/A
- GRI N/A
- Revenue
- YOSH $11,652,880.00
- GRI N/A
- Revenue This Year
- YOSH N/A
- GRI N/A
- Revenue Next Year
- YOSH N/A
- GRI N/A
- P/E Ratio
- YOSH N/A
- GRI N/A
- Revenue Growth
- YOSH 25.97
- GRI N/A
- 52 Week Low
- YOSH $2.71
- GRI $0.30
- 52 Week High
- YOSH $16.50
- GRI $12.31
- Technical
- Relative Strength Index (RSI)
- YOSH 54.11
- GRI 28.18
- Support Level
- YOSH $3.83
- GRI $0.43
- Resistance Level
- YOSH $16.50
- GRI $0.60
- Average True Range (ATR)
- YOSH 2.79
- GRI 0.06
- MACD
- YOSH 0.29
- GRI -0.00
- Stochastic Oscillator
- YOSH 41.36
- GRI 10.91
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.